Over the course of 2021, lawmakers, government officials and the FDA's top brass have wracked their brains for a solution to the agency's hefty drug manufacturing inspection backlog. The regulator has ...

Thanks to shortfalls at a manufacturing plant, Bristol Myers Squibb won't be shelling out a closely watched follow-up payment linked to its Celgene buyout. And disappointed investors—who'd been hotly ...